; and (2) a pharmacy, pharmacist, or a pharmacy's contracting agent, such as a pharmacy services administrative organization, may contain a provision prohibiting or penalizing (including through increased utilization review, reduced payments, or other financial disincentives) a pharmacist’s disclosure to an individual purchasing a prescription drug of information regarding the cost of the prescription drug to the individual (including any copayment or coinsurance), or regarding the availability of any therapeutically equivalent alternative drug, or alternative methods of purchasing the prescription drug (including paying a cash price), that are less expensive than the cost of the prescription drug to the individual. (b) Null and void Any provision described in subsection (a) in a contract described in subsection (a) is null and void. (c) Applicability Subsection (a) applies only with respect to contracts, and contract addenda, entered into or renewed on or after the date of enactment of the Prescription Transparency Act of 2018 . (d) Regulations and guidance The Secretary may issue such regulations and guidance as may be necessary for implementation of this section. (e) Definitions In this section: (1) The term drug has the meaning given to such term in section 201 of the Federal Food, Drug, and Cosmetic Act. (2) The term health insurer means a health insurance issuer (as defined in section 2791) offering health insurance coverage (as defined in such section) in the individual or group market or a sponsor of a group health plan (as defined in such section). (3) The term prescription drug means a drug subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act. .